GlassScriptPhysician profile
Laura Donarummo
NPI 1922265859
$719.92
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.97 · 2020: $105 · 2021: $167 · 2022: $139 · 2023: $104 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $114.23 | 2023-2024 | Qulipta, Ubrelvy |
| Biohaven Pharmaceutical Holding Company LTD. | $95.06 | 2022 | |
| Braemar Manufacturing, LLC | $92.97 | 2019 | |
| Sk Life Science, INC. | $74.15 | 2020-2021 | |
| Amgen INC. | $68.85 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $50.50 | 2021 | |
| Lundbeck LLC | $35.68 | 2023 | Vyepti |
| Sunovion Pharmaceuticals INC. | $29.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.30 | 2020 | |
| Arbor Pharmaceuticals, INC. | $25.22 | 2021 | |
| Neurocrine Biosciences, INC. | $25.12 | 2024 | Ingrezza |
| Upsher-Smith Laboratories LLC | $21.46 | 2020 | |
| Sumitomo Pharma America, INC. | $21.05 | 2023 | Aptiom |
| Amneal Pharmaceuticals LLC | $20.19 | 2024 | Ongentys |
| Biohaven Pharmaceuticals, INC. | $19.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Donarummo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.